Main Inclusion Criteria:  Subject with a history of Cholinergic urticaria diagnosis for ≥ 6 months  Subject has active and uncontrolled Cholinergic urticaria disease at the time of screening and randomisation, as defined by the following:  Urticaria control test < 12 at screening Urticaria Activity Score post-provocation ≥ 3 Recent history (within 6 months of screening) with documented inadequate response to standard dose as to marketing authorization of H1 antihistamines.  Main Exclusion Criteria:  Other clearly dominating forms* of urticaria as aetiology for wheal and flare type reactions  *These diseases are allowed as comorbidities, if cholinergic urticaria is the dominating form of chronic urticaria,  Systemic immunosuppressive medications within 4 weeks prior to screening, Systemic drugs (e.g. oral drug) with antihistamine properties including H1 antihistamines and some antidepressants (e.g. tricyclic antidepressants) and H2 antihistamines 1 week prior to randomisation and throughout the trial. However, topical antihistamines in the form of nasal spray and eyedrops are allowed in the standard prescribed dose.